Literature DB >> 2071302

Administration of IL-2-PE40 via osmotic pumps prevents adjuvant induced arthritis in rats. Improved therapeutic index of IL-2-PE40 administered by continuous infusion.

H Lorberboum-Galski1, R Lafyatis, J P Case, D FitzGerald, R L Wilder, I Pastan.   

Abstract

IL-2-PE40 is a chimeric cytotoxin composed of interleukin 2 (IL-2) fused to a truncated form of Pseudomonas exotoxin (PE) that lacks its binding domain. IL-2-PE40 has been shown to exhibit therapeutic potency in several models in vivo when administered i.p. twice a day. Here we show that the continuous administration of IL-2-PE40 by an osmotic pump specifically prevents the development of adjuvant induced arthritis in rats with an improved therapeutic efficacy as compared to daily repeated i.p. injections. Stabilization of IL-2-PE40 at 37 degrees C for the continuous administration by pumps was achieved by adding NAD, the substrate for the enzyme portion of the chimeric toxin.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2071302     DOI: 10.1016/0192-0561(91)90112-k

Source DB:  PubMed          Journal:  Int J Immunopharmacol        ISSN: 0192-0561


  6 in total

1.  In vivo cyclooxygenase expression in synovial tissues of patients with rheumatoid arthritis and osteoarthritis and rats with adjuvant and streptococcal cell wall arthritis.

Authors:  H Sano; T Hla; J A Maier; L J Crofford; J P Case; T Maciag; R L Wilder
Journal:  J Clin Invest       Date:  1992-01       Impact factor: 14.808

2.  An in situ cross-linking hybrid hydrogel for controlled release of proteins.

Authors:  Hila Epstein-Barash; Cristina F Stefanescu; Daniel S Kohane
Journal:  Acta Biomater       Date:  2012-02-08       Impact factor: 8.947

3.  Effect of IL-2-Bax, a novel interleukin-2-receptor-targeted chimeric protein, on bleomycin lung injury.

Authors:  Michael J Segel; Rami Aqeilan; Keren Zilka; Haya Lorberboum-Galski; Shulamit B Wallach-Dayan; Michael W Conner; Thomas G Christensen; Raphael Breuer
Journal:  Int J Exp Pathol       Date:  2005-10       Impact factor: 1.925

4.  Coexpression of phosphotyrosine-containing proteins, platelet-derived growth factor-B, and fibroblast growth factor-1 in situ in synovial tissues of patients with rheumatoid arthritis and Lewis rats with adjuvant or streptococcal cell wall arthritis.

Authors:  H Sano; K Engleka; P Mathern; T Hla; L J Crofford; E F Remmers; C L Jelsema; E Goldmuntz; T Maciag; R L Wilder
Journal:  J Clin Invest       Date:  1993-02       Impact factor: 14.808

5.  Construction of an immunotoxin, HN3-mPE24, targeting glypican-3 for liver cancer therapy.

Authors:  Chunguang Wang; Wei Gao; Mingqian Feng; Ira Pastan; Mitchell Ho
Journal:  Oncotarget       Date:  2017-05-16

Review 6.  Glypican-3 Targeting Immunotoxins for the Treatment of Liver Cancer.

Authors:  Bryan D Fleming; Mitchell Ho
Journal:  Toxins (Basel)       Date:  2016-09-22       Impact factor: 4.546

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.